Ranitidine was exempt from price control under the provisions of the Drugs (Prices Control) Order, 1987 for 5 years. On the expiry of this period, the BICP has been asked to conduct Cost-cum-Technical Study of this bulk drug. Sale price of this bulk drug manufactured by various producers would also be considered by the BICP while conducting this study.

(d) No, Sir.

New Drug Policy

884. PROF. I. G. SANADI:
DR. NARREDDY THULASI REDDY:

Will the PRIME MINISTER be pleased to state:

(a) at what stage the New Drug Policy stands at present:

(b) when would it be announced and what objective are sought to be achieved:

(c) how justice to consumers is sought to be done;

(d) whether the impact of the proposed policy on price increases has been studied and if so, what are the details in this regard;

(e) whether the Ministry has made any study on price increases of medicines under the existing policy and if so, what are the reasons for such high increases:

(f) whether it is also a fact that price increases of medicines are proposed to be linked to increase in wholesale price index and not based on actual increases in costs or whole price index of chemicals; and

(g) if so, what would be its effect on price increases?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS WITH ADDITIONAL CHARGE OF THE MINISTER OF STATE IN THE MINISTRY OF PARLIAMENTARY AFFAIRS AND MINISTER OF STATE IN THE DEPARTMENT OF ELECTRONICS AND THE MINISTER OF STATE IN THE DEPARTMENT OF OCEAN DEVELOPMENT (SHRI EDUARDO FALEIRO): (a) to (g) The discussions on the various aspects of the Drug Policy, 1986 have taken place in the House on 18th, 19th and 23rd August, 1993. Final decisions in this regard are still to be taken. Due care is being taken to see that there is no spurt in the prices of medicines.

Operation of M/s. Rhone Poulanc

885. PROF. I. G. SANADI:
DR. NARREDDY THULASI REDDY:

Will the PRIME MINISTER be pleased to state:

(a) whether M/s. Rhone Poulanc have failed to produce any bulk drug from basic stages inspite of specific conditions in their industrial licences;

(b) whether it is a fact that they are over invoicing the imports and have refrained from investments due to respite provided by Government;

(c) the reasons for which the conditions of the approvals and commitments given by the company were not enforced:

(d) what are the intermediates being imported by them in violation of the conditions and without resorting to basic production which they were expected to undertake; and

(e) what are the names of drugs being produced by this company and from which stage and what is the stage allowed in each case?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS WITH ADDITIONAL CHARGE OF THE MINISTER OF STATE IN THE MINISTRY OF PARLIAMENTARY AFFAIRS AND MINISTER OF STATE IN THE DEPARTMENT OF ELECTRONICS AND DEPARTMENT OF OCEAN DEVELOPMENT (SHRI EDUARDO FALEIRO): (a) to (e) Details will be collected and placed on the Table of the House.